PTC THERAPEUTICS, INC.

PTCTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1070081

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$937.8M	$698.8M	$538.6M	$380.8M	$307.0M
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$666.6M	$651.5M	$540.7M	$477.6M	$257.5M
Selling, General and Administrative Expense	$332.5M	$326.0M	$285.8M	$245.2M	$202.5M
Operating Expenses	$1.4B	$1.1B	$913.0M	$812.5M	$548.1M
Operating Income (Loss)	-$439.5M	-$447.4M	-$374.4M	-$431.8M	-$241.2M
Other Nonoperating Income (Expense)	$10.1M	-$49.2M	-$57.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.7B	$1.9B	$1.7B	$1.9B	$2.2B
Assets, Current	$1.4B	$1.2B	$693.8M	$954.4M	$1.2B
Cash and Cash Equivalents, at Carrying Value	$779.7M	$594.0M	$279.8M	$189.7M	$208.8M
Inventory, Net	$23.2M	$30.6M	$21.8M	$15.9M	$18.7M
Liabilities	$2.8B	$2.7B	$2.1B	$1.9B	$1.7B
Liabilities, Current	$581.0M	$603.1M	$406.2M	$509.3M	$277.3M
Accounts Payable, Current	$17.3M	$6.0M	$27.3M	$23.0M	$18.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$158.4M	-$356.7M	-$251.3M	-$194.1M	-$98.6M
Net Cash Provided by (Used in) Investing Activities	-$176.7M	$290.2M	$219.2M	-$561.5M	-$387.2M
Net Cash Provided by (Used in) Financing Activities	$646.4M	$168.0M	$20.9M	$668.7M	$613.2M
Payments to Acquire Property, Plant, and Equipment	$28.4M	$32.0M	$28.2M	$17.8M	$13.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)